AJAlexander Juto

Alexander Juto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander Juto has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microsaccade rate dynamics and kinematic correlates of motor severity and episodic memory in Parkinson's disease

    by Theodora Soumala, Panagiota Tsitsi, Yiting Wang, Alexander Juto, Caroline Ingre, Mattias Nilsson, Per Svenningsson, Ioanna Markaki

    BackgroundOculomotor abnormalities are well documented in Parkinson's disease, but the behavior of microsaccades - small fixational eye movements regulated by distributed oculomotor networks - and their clinical relevance remain poorly characterized. ObjectiveTo characterize microsaccade kinematics and temporal dynamics during a structured fixation paradigm in persons with Parkinson's disease (PwPD), and to examine associations with motor severity, episodic memory, and global cognitive performance. MethodsMicrosaccades were recorded using a 1200 Hz eye tracker during an 8-trial fixation paradigm in 46 PwPD and 40 matched healthy controls. Kinematic features and rate were analyzed across groups and examined for associations with clinical scales (Hoehn & Yahr, Montreal Cognitive Assessment, Mini-Mental State Examination, Frontal Assessment Battery) using logistic regression with FDR correction. ResultsPwPD showed nominally higher microsaccade amplitude, distance, and peak velocity than healthy controls, differences that did not survive FDR correction (p-FDR=0.054). Microsaccade rate increased progressively across consecutive trials in both groups (PD: β=0.04, p-FDR=0.001; HC: β=0.06, p-FDR<0.001), indicating temporal instability in fixational behavior within brief observation windows. In PwPD, higher microsaccade rate was independently associated with more advanced disease stage (H&Y; OR=2.77, 95% CI 1.40–5.47), and larger amplitude and distance were associated with worse episodic memory performance (MMSE delayed recall; amplitude OR=0.42, 95% CI 0.23–0.78; distance OR=0.39, 95% CI 0.20–0.76). All clinical associations survived FDR correction. ConclusionsDistinct microsaccade features emerge as candidate indices of motor severity and episodic memory function in PD. Progressive within-session rate changes should be accounted for in the design of future oculomotor studies.

  • Open Access

    Plasma cardiac troponin T as a marker of skeletal muscle involvement in amyotrophic lateral sclerosis

    by Linn Öijerstedt, Jianing Lin, Aditya Singh, Solmaz Yazdani, Annamari M Saarinen, Ulf Kläppe, Alexander Juto, Sanharib Chamoun, Sofia Imrell, Fang Fang, et al.

    Plasma cardiac troponin T (cTnT) is widely used as a marker of myocardial injury, yet recent studies suggest elevations in amyotrophic lateral sclerosis (ALS). Whether these elevations reflect disease-associated skeletal muscle remodelling remains unresolved. In this translational study, we analysed longitudinal plasma cTnT in a large clinical cohort comprising 496 patients with ALS and 84 with benign fasciculation syndrome (BFS). To investigate the biological origin of circulating cTnT, we examined publicly available skeletal muscle transcriptomes from patients with ALS (n = 28) and healthy controls (n = 17), and quantified troponin isoform expression in skeletal muscle from SOD1G93A mice and wild-type littermates. Plasma cTnT was significantly higher in ALS than in BFS (median 18 versus 6 ng/L, P = 3.6 × 10−27), with 57% of patients with ALS exceeding the cardiologic threshold of 15 ng/L. Diagnostic performance was high [area under the curve (AUC) 0.87], with excellent specificity (94%). Longitudinal modelling revealed a progressive increase in cTnT in ALS whereas levels remained stable in BFS. Skeletal muscle transcriptomics demonstrated robust upregulation of TNNT2, encoding cardiac troponin T, in ALS muscle, while other troponin isoforms were unchanged. In SOD1G93A mice, severely affected gastrocnemius muscle exhibited isoform-specific remodelling, including 20-fold upregulation of Tnnt2 and slow-fibre troponins, alongside downregulation of fast skeletal isoforms. Across clinical, transcriptomic, and experimental data, elevated plasma cTnT in ALS is best explained by disease-associated skeletal muscle remodelling rather than cardiomyocyte injury. Plasma cTnT emerges as a dynamic and accessible biomarker in ALS capturing muscle involvement. Prospective incorporation of cTnT into clinical trials and evaluation across broader neuromuscular differentials are warranted.

  • Open Access

    Muscle proteins in plasma associate to distinguished phenotypes in amyotrophic lateral sclerosis

    by Louisa Azizi, Inci S. Aksoylu, María Bueno Álvez, Juliette Foucher, Alexander Juto, Christina Seitz, Raymond Press, Kristin Samuelsson, Ulf Kläppe, Mathias Uhlén, et al.

    Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by death of upper and lower motor neurons, usually presented with clinical heterogeneity. Fluid biomarker development remains dominated by neurofilament light chain (NEFL), a marker of neuroaxonal injury. NEFL is however unspecific to ALS and its phenotypes and there is currently a lack of biomarkers that capture ALS heterogeneity such as onset site and ALS-frontotemporal spectrum disorder (ALS-FTSD). Therefore, we investigated whether plasma proteomics could reveal pathway-level signatures that stratify and explain ALS heterogeneity. Methods: We profiled ∼5,400 plasma proteins (Olink Explore HT) in 299 patients with ALS and 50 age- and sex comparable healthy controls. We used two complementary analytic frameworks: (i) differential protein abundance analysis to identify altered proteins in ALS and across clinical subgroups, and (ii) weighted gene correlation network analysis (WGCNA) to identify coordinated protein modules and relate them to ALS diagnosis and to ALS-specific clinical traits (site of onset, ALS-FTSD, ALS functional rating scale-revised (ALSFRS-R) score, and plasma NEFL). Results: Differential abundance analysis identified 56 proteins altered in ALS versus controls, of which 40 were increased. WGCNA identified 11 co-expression modules, with ALS samples having the strongest correlation to a protein module (n=51) highly enriched for muscle-related proteins. Out of the 40 proteins that had increased expression levels, 29 overlapped with the muscle-enriched protein module, indicating that muscle related proteins are the dominant circulating proteomic signature in ALS. This signal extended to clinical stratification: spinal-onset patients showed a strong positive association with the muscle-module. Further, differential abundance analysis of spinal- versus bulbar-onset ALS identified changes that mapped predominantly to the same module, supporting a molecular signature of onset phenotype. In contrast, cognitive status (ALS-FTSD) mapped to distinct modules enriched for extracellular matrix/cell-adhesion pathways, consistent with a separable biological axis of disease heterogeneity. Although multiple modules correlated with NEFL, trait-specific signatures were not fully explained by neuroaxonal injury. Notably, the muscle-enriched module increased with higher NEFL and lower ALSFRS-R, supporting its interpretation as a severity-linked, muscle-involvement proxy. Conclusions: Large-scale plasma proteomics reveals that heterogeneity in ALS reflects underlying biological structures. We identified a dominant muscle-associated protein network that distinguished ALS patients from controls and correlated with disease onset phenotype and severity, alongside distinct protein networks linked to ALS-FTSD. By integrating differential protein abundance with network-based analysis, we defined pathway-level biomarker signatures that extend beyond NEFL, enabling biologically informed patient stratification and improved therapeutic monitoring.


  • Open Access

    Venous Bicarbonate as a Prognostic Biomarker and Proposed Proxy for Vital Capacity to Be Used as an Eligibility Criterion in Amyotrophic Lateral Sclerosis Clinical Trials

    by Juliette Foucher, Therese Wellander, Anikó Lovik, Linn Öijerstedt, Alexander Juto, Fang Fang, Caroline Ingre

    Background: Clinical trials for people living with ALS (pALS) all list vital capacity (VC) as an important eligibility criterion. However, VC measures are challenging to perform among pALS, especially bulbar pALS. Additionally, since the disease rapidly changes, the VC can change in a short duration of time, making it unreliable.Objective: We aimed to investigate the association of venous bicarbonate with VC as an alternative criterion for trial eligibility. We also wanted to examine whether venous bicarbonate could be used as a prognostic biomarker for survival in ALS.Methods: We included pALS from the Swedish ALS/MND Registry between January 1, 2019 and July 31, 2022. pALS had to have serum bicarbonate values and ALSFRS‐R available close to diagnosis. Spearman correlations, Kaplan–Meier curves, and Cox proportional hazard regressions were used to assess the associations of venous bicarbonate with VC, other clinical characteristics, and survival.Results: Among the 117 pALS included in the study, we observed a negative correlation between venous bicarbonate and VC among spinal and bulbar pALS (ρ = −0.346, p = 0.002 and ρ = −0.367, p = 0.024, respectively). Venous bicarbonate negatively correlated with ALSFRS‐R (ρ = −0.377, p < 0.001), specifically among bulbar pALS (ρ = −0.595, p < 0.001), but positively correlated with KING's stage (ρ = 0.248, p = 0.007). High level of venous bicarbonate appeared to be associated with shorter survival.Conclusions: Venous bicarbonate appears to be a prognostic biomarker for survival among pALS. This cheap and easily accessible measure could potentially be an alternative for VC as an eligibility criterion in ALS trials.


  • Open Access

    Plasma troponin T reflects lower motor neuron involvement on electromyography in amyotrophic lateral sclerosis

    by Sanharib Chamoun, Sofia Imrell, Zane Upate, Ulf Kläppe, Linn Öijerstedt, Solmaz Yazdani, Mikael Andersson Franko, Juliette Foucher, Louisa Azizi, Anikó Lovik, et al.

    Cardiac troponin T (cTnT) is elevated in neuromuscular conditions without apparent cardiac disease, including Amyotrophic Lateral Sclerosis (ALS). The reason for this increase is unclear. Since cTnT is found in both cardiomyocytes and skeletal muscle cells, we aimed to investigate the latter as a possible cTnT source. We examined the correlation of cTnT in venous blood to lower motor neuron (LMN) involvement on Electromyography (EMG). A positive correlation between EMG findings and cTnT levels would indicate that cTnT is a biomarker for LMN involvement in ALS. This observational cohort study was conducted on a tertiary referral centre for neuromuscular diseases in Stockholm, Sweden. Consecutive patients with ALS were included. EMG was performed during diagnostic work-up, and high-sensitive cardiac troponin T (hs-cTnT), plasma creatine kinase (CK), and serum neurofilament light (NfL) were analysed within 6 months of the EMG. King's stage and score on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) closest to hs-cTnT sampling were noted. In total, 50 ALS patients diagnosed between 1 January 2014 and 31 December 2018 were included and followed until death, invasive ventilation, or the 14 August 2024. Hs-cTnT correlated positively with the number of muscular regions involved (τ = 0.283, P = 0.009) and percentage of muscles involved on EMG (ρ = 0.367, P = 0.009). Hs-cTnT was associated with the percentage of muscles involved in EMG in the adjusted linear regression. Patients with higher hs-cTnT had more advanced King's stage, both when numerical hs-cTnT and subgrouping high (≥15 nanogram/L) versus normal hs-cTnT was used (τ = 0.253, P = 0.021 and U = 197.5, P = 0.022, respectively). Hs-cTnT was neither correlated to ALSFRS-R total score (ρ = −0.176, P = 0.220 and U = 249.5, P = 0.233, respectively) nor ALSFRS-R excluding respiratory domain score (ρ = −0.069, P = 0.632 and U = 280.5, P = 0.558, respectively). High versus normal hs-cTnT did not predict survival (univariate analysis, HR = 1.824, P = 0.060). Numerical hs-cTnT was associated with shorter survival (univariate analysis, HR = 1.635, P = 0.017) but not after adjusting for age at diagnosis (HR = 1.413, P = 0.105). This study illustrates that ALS patients with higher hs-cTnT have more spread disease as evidenced by the positive correlation between hs-cTnT and both EMG and King's stage. This is not true for established biomarkers of muscle damage (CK) and neuroaxonal damage (NfL). These findings need to be confirmed in larger studies but suggest that hs-cTnT is a biomarker of LMN involvement in patients with ALS and could be used in clinical trials.


  • Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies

    by Nicky Dunn, Alexander Juto, Malin Ryner, Ali Manouchehrinia, Luca Piccoli, Katharina Fink, Fredrik Piehl, Anna Fogdell-Hahn

    Background: Rituximab is a chimeric monoclonal anti-CD20 B-cell-depleting antibody increasingly used off-label in multiple sclerosis (MS). The clinical relevance of anti-drug antibodies (ADAs) against rituximab in MS is unknown. Objective: To determine frequency of ADA in relation to B-cell counts, allergic reactions and clinical efficacy in a large cohort of MS-treated patients. Methods: Cross-sectional study with collection of serum samples from 339 MS patients immediately before a scheduled rituximab infusion. ADAs were detected using an in-house–validated electrochemiluminescent immunoassay and a commercial enzyme-linked immunosorbent assay (ELISA) to compare methods. Data on patient demographics and clinical outcomes were retrieved from the Swedish MS Registry and patient records. Results: ADAs were detected in 37% of relapsing–remitting MS and 26% in progressive forms of MS. Presence of ADAs decreased with increasing number of rituximab infusions. There was a significant association between both presence and titres of ADAs and incomplete B-cell depletion, but not with infusion/adverse reactions or clinical outcomes at the group level. Only five patients terminated rituximab during follow-up, four of which were ADA positive. Conclusion: Rituximab treatment is associated with a high degree of ADAs, which correlates with efficacy of B-cell depletion; however, the clinical relevance of ADAs remains uncertain.